Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Paxinos, Charles Watson (1983)
The Rat Brain in Stereotaxic Coordinates
B. Valastro, A. Dekundy, Morten Krogh, M. Lundblad, P. James, W. Danysz, G. Quack, M. Cenci (2007)
Proteomic analysis of striatal proteins in the rat model of l‐DOPA‐induced dyskinesiaJournal of Neurochemistry, 102
(2006)
Stable rotigotine plasma concentrations over 24 hours in patients with early-stage Parkinson’s disease after once-daily transdermal administration of rotigotine (Neupro (R))
M. Cenci (2002)
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's diseaseAmino Acids, 23
C. Guigoni, E. Doudnikoff, Qin Li, B. Bloch, E. Bézard (2007)
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.Neurobiology of disease, 26 2
Shuting Gu, Hai Huang, Jianqing Bi, Yuan Yao, T. Wen (2009)
Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat modelBrain Research, 1257
M. Steiger (2007)
Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's diseaseEuropean Journal of Neurology, 15
C. Jacob, E. Koutsilieri, Jasmin Bartl, E. Neuen‐Jacob, T. Arzberger, N. Zander, R. Ravid, W. Roggendorf, P. Riederer, E. Grünblatt (2007)
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease.Journal of Alzheimer's disease : JAD, 11 1
W. Schmidt, H. Lebsanft, M. Heindl, M. Gerlach, E. Gruenblatt, P. Riederer, A. Mayerhofer, D. Scheller (2008)
Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movementsJournal of Neural Transmission, 115
P Jenner (2008)
Molecular mechanisms of l -DOPA-induced dyskinesiaNat Rev Neurosci, 9
E. Grünblatt, S. Hoyer, P. Riederer (2004)
Gene expression profile in streptozotocin rat model for sporadic Alzheimer’s diseaseJournal of Neural Transmission, 111
C. Konradi, J. Westin, M. Carta, Molly Eaton, K. Kuter, A. Dekundy, M. Lundblad, M. Cenci (2004)
Transcriptome analysis in a rat model of l-DOPA-induced dyskinesiaNeurobiology of Disease, 17
O. Halbach, L. Minichiello, K. Unsicker (2005)
Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of α‐synuclein in the substantia nigraThe FASEB Journal, 19
J. Jankovic (2005)
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestationsMovement Disorders, 20
S. Apfel (1999)
Neurotrophic Factors in Peripheral Neuropathies: Therapeutic ImplicationsBrain Pathology, 9
K. Stockwell, Doreen Scheller, L. Smith, S. Rose, M. Iravani, M. Jackson, P. Jenner (2010)
Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosetsExperimental Neurology, 221
G. Fisone, E. Bézard (2011)
Molecular mechanisms of l-DOPA-induced dyskinesia.International review of neurobiology, 98
Nir Giladi, B. Boroojerdi, A. Korczyn, D. Burn, C. Clarke, A. Schapira (2007)
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropiniroleMovement Disorders, 22
G. Metz, A. Tse, M. Ballermann, L. Smith, K. Fouad (2005)
The unilateral 6‐OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysisEuropean Journal of Neuroscience, 22
T. Maeda, K. Nagata, Y. Yoshida, K. Kannari (2005)
Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPABrain Research, 1046
J. Brotchie (2005)
Nondopaminergic mechanisms in levodopa‐induced dyskinesiaMovement Disorders, 20
M. Cenci (2007)
Dopamine dysregulation of movement control in l-DOPA-induced dyskinesiaTrends in Neurosciences, 30
E. Grünblatt, S. Mandel, J. Jacob-Hirsch, S. Zeligson, N. Amariglo, G. Rechavi, J. Li, R. Ravid, W. Roggendorf, P. Riederer, M. Youdim (2004)
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genesJournal of Neural Transmission, 111
A. Evaluation, Wolters Kluwer, D. Nyholm, N. Quinn, O. Rascol, D. Silver, C. Waters (2007)
Rotigotine Transdermal Patch A Review of its Use in the Management of Parkinson's Disease
T. Chase (2004)
Striatal plasticity and extrapyramidal motor dysfunction.Parkinsonism & related disorders, 10 5
Zhi-quan Li, Yun-yu Hu, Qingsheng Zhu, Jinyu Zhu (2008)
Neurotrophin-3 reduces apoptosis induced by 6-OHDA in PC12 cells through Akt signaling pathwayInternational Journal of Developmental Neuroscience, 26
M. Alam, W. Schmidt (2004)
l-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated ratsBehavioural Brain Research, 153
J. Nutt (2007)
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?Movement Disorders, 22
V. Sgambato-Faure, V. Buggia, F. Gilbert, D. Lévesque, A. Benabid, F. Berger (2005)
Coordinated and Spatial Upregulation of Arc in Striatonigral Neurons Correlates With L-Dopa-Induced Behavioral Sensitization in Dyskinetic RatsJournal of Neuropathology and Experimental Neurology, 64
M. Cenci, C. Lee, A. Björklund (1998)
L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNAEuropean Journal of Neuroscience, 10
M. Morelli, S. Fenu, A. Cozzolino, G. Chiara (1991)
Positive and negative interactions in the behavioural expression of d1 and D2 receptor stimulation in a model of parkinsonism: Role of primingNeuroscience, 42
J. Vandesompele, K. Preter, F. Pattyn, B. Poppe, N. Roy, A. Paepe, F. Speleman (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genesGenome Biology, 3
Continuous dopaminergic treatment is considered to prevent or delay the occurrence of dyskinesia in patients with Parkinson’s disease (PD). Rotigotine is a non-ergolinic D 3 > D 2 > D 1 dopamine-receptor agonist for the treatment of PD using a transdermal delivery system providing stable plasma levels. We aimed to investigate the differential influence on gene expression of pulsatile l -DOPA or rotigotine versus a continuous rotigotine treatment. The gene expression profile within the nigro-striatal system of unilateral 6-hydroxydopamine-lesioned rats was assessed in order to differentiate potential changes in gene expression following the various treatment using Affymetrix microarrays and quantitative RT-PCR. The expression of 15 genes in the substantia nigra and of 11 genes in the striatum was altered under pulsatile treatments inducing dyskinetic motor response, but was unchanged under continuous rotigotine treatment that did not cause dyskinetic motor response. The route of administration of a dopaminergic drug is important for the induction or prevention of motor abnormalities and adaptive gene expressions. The decline of neurotrophin-3 expression under pulsatile administration was considered of particular importance.
Journal of Neural Transmission – Springer Journals
Published: Dec 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.